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Background: Human Immunodeficiency Virus (HIV) infection is a risk factor for tuberculosis (TB). Antiretroviral
therapy (ART) changed HIV clinical management but it is still unclear how pre-existing HIV/Mycobacterium
tuberculosis (Mtb)-specific CD4+ and CD8+ T-cells are restored.
Aim: to evaluate the impact of ART and TB therapies on the functional and phenotypic profile of Mtb-specific
antigen-response of CD4+ and CD8+ T-cells in prospectively enrolled HIV-TB co-infected patients.
Methods: ART-naïve HIV-infected patients, with or without active TB or latent TB infection (LTBI), were enrolled
before and after starting ART and TB therapies. Peripheral blood mononuclear cells (PBMC) were stimulated
overnight with Mtb and HIV antigens (GAG). Cytokine expression and phenotype profile were evaluated by flow
cytometry. Cytomegalovirus (CMV) and staphylococcal enterotoxin B (SEB) were also used.
Results: The median of absolute number of CD4+ T-cells increased after ART and TB therapies in all groups
analyzed, while the median of absolute number of CD8+ T-cells decreases in HIV and HIV-LTBI groups.
Treatments significantly increased the frequency of Mtb-specific CD4+ T-cells in the HIV-LTBI (p= 0.015) with
a rise of the central memory compartment. The magnitude of the CD4+ T-cell response to HIV-GAG significantly
increased in active TB (p= 0.03), whereas the magnitude of CMV-specific CD4+ T-cell response decreased in all
the groups. Similarly, the treatments increased the number of Mtb-specific CD8+ responders in both HIV-LTBI
and HIV-TB groups, whereas the phenotype distribution was dependent on the antigens used and on the stage of
infection/disease.
Conclusions: After therapies the median of absolute number and the proportion of CD4+ T-cells increased in all
groups whereas the median of absolute count and proportion of CD8+ T-cells decreased in the HIV and HIV-LTBI
subjects. Interestingly, an increased frequency of CD4+ T-cell response to RD1 proteins in HIV-LTBI subjects was
found. These results contribute to a better understanding of the effect of ART and TB therapies on the modulation
of Mtb-specific CD4+ and CD8+ T-cells subsets.
1. Introduction
It is estimated that about one fourth of the world's population is
infected with Mtb [1]. In 2016, an estimated 1.0 million (10%) of the
10.4 million people who developed TB worldwide were HIV-infected. In
these subjects, HIV infection leads a risk of progression to active TB
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disease that is 21 times greater than individuals who do not have HIV
infection [2].
In fact, HIV infection is one of the main and most well known cause
for the establishment of active TB disease even at the stage where a
profound deficit of CD4+ T-cells count is not yet present [3]. Data
suggest that the condition of co-infection HIV-Mtb accelerates the
progression of both diseases [4–6]. It has been reported that macro-
phages co-infected in vitro presented higher number of viral copies due
to an increase of the HIV replication [7,8]. Probably, the state of im-
mune activation established during TB infection creates an optimal
cytokine micro-environment for HIV replication [7,9,10] while the
state of immune deficiency could cause an increase of the morbidity
and mortality in the co-infection.
ART has significantly changed the clinical outcome of the HIV-in-
fected patients, leading to a decrease of the morbidity and mortality
through a reduction of plasma viral copies and an increase of absolute
count of CD4+ T-cells [11,12]. Although the clinical improvement due
to the ART is evident, many aspects remain to be understood, in par-
ticular how far the immune function level is completely restored [13].
HIV-infected patients treated with ART show a variable capacity to re-
establish the different co-pathogen specific CD4+ T-cell responses, de-
pending on the nature of pathogen that they identify [14–16]. Re-
garding the Mtb-specific CD4+ T-cell response, controversial data exist
on its restoration upon ART.
CD4+ and CD8+ T-cells show distinct characteristics depending on
their differentiation stage [17,18]. Based on the expression of two dif-
ferent and conventional markers, CD45RA and CCR7, is possible to
identify different T-cell subpopulations namely: naïve (N), referred to
CD45RA+ CCR7+ cells; central memory (CM), as CD45RA− CCR7+;
effector memory (EM), as CD45RA− CCR7−; and terminally differ-
entiated effector memory (E) T-cells, as CD45RA+ CCR7− [19].
Studies evaluating the Mtb-response in terms of cytokine profile in
HIV co-infected patients naïve or not to ART report contrasting findings
[20–24]. Indeed, both polyfunctional and monofunctional cytokine T-
cell subsets have been observed in HIV-TB patients and HIV-LTBI
[20,22–26]. Sutherland et al. observed that ART therapy induces an
increase of the polyfunctional Mtb-specific CD4+ T-cell responses
compared to the baseline condition [23], whereas the results of a cross-
sectional study of ART-naïve and ART-treated individuals show no
significant difference in the frequency and profile of polyfunctional
Mtb-specific CD4+ T-cell responses [27].
At the moment it is unclear the impact of ART and TB treatments on
the CD4+ and CD8+ T-cells simultaneously evaluated in terms of cy-
tokine expression and maturation phenotype of patients with both co-
infections. Therefore, aim of the present study was to assess the role of
these therapies in HIV-infected patients naïve to ART with or without
Mtb infection (active TB or LTBI) on the absolute number of CD4+ and
CD8+ T-cells, on the total cytokine production and memory profile of
Mtb-specific antigen-response in comparison with other recall antigen
responses, as that to HIV-GAG or CMV.
2. Materials and methods
2.1. Study population and sample collection
This study was conducted at the National Institute of Infectious
diseases (INMI) L. Spallanzani and approved by the INMI Ethical
Committee (approval number 34/2011). Informed written consent was
required to participate in the study. A total of 86 HIV-infected and naïve
to ART patients were prospectively enrolled (from 2012 to 2015). They
were recently diagnosed for HIV infection, but were not recent infec-
tions. Twelve active-TB (HIV-TB) patients were enrolled within 7 days
of starting the TB-specific treatment. Active TB microbiologically di-
agnosed was defined based on the Mtb isolation from sputum culture.
Active TB clinically diagnosed was defined based on the clinical and
radiological lung lesions associated with TB in the absence of Mtb
isolated in the sputum that completely recovered after TB-specific
treatment for 6 months. Microbiological TB was characterized by first
line Mtb drug-sensitive isolates. In the absence of clinical, micro-
biological and radiological signs of active TB, LTBI was defined based
on a positive score to QFT-GIT (Qiagen, Hilden, Germany) [28]. TB
therapy was performed for 6 months, as indicated by the standard
procedures [29]. We initially prospectively enrolled 86 ART naïve HIV-
infected patients. They were compliant to both therapies (ART and/or
TB-specific treatment). However most of them were not willing to
participate to the study the second time, therefore only 24 (28%) were
followed overtime: 8 without TB co-infection (HIV), 7 HIV-LTBI and 9
HIV-TB (6 microbiologically diagnosed and 3 clinically diagnosed)
(Fig. 1). Around 70% of the patients followed overtime were BCG-
vaccinated; regarding the origin, almost 33% were from South America,
29% from Italy and 21% from Eastern Europe. No significant difference
in age or origin was observed comparing all groups while the gender
distribution was significantly different among the groups, 50% of fe-
male subjects in HIV group, 14.3% and 0% of females subjects in HIV-
LTBI and HIV-TB groups respectively (Table 1).
2.2. Stimuli
PBMC were stimulated for 16 h with Mtb-specific antigens: a) a mix
of recombinant proteins ESAT-6 and CFP-10 (Lionex, Braunschweig,
Germany) (hereafter referred to as RD1 proteins) at 4 μg/ml with a
contamination of lipopolysaccharide reported by the manufacturer of
less than 0.05 IU/mg for ESAT-6 and equal to 66.7 IU/mg for CFP-10; b)
a pool of synthetic overlapping peptides (15 AA in length, with 11 AA of
overlapping sequential peptides) corresponding to ESAT-6 and CFP-10
sequences (INBIOS, Naples, Italy) used at 2 μg/ml (hereafter referred to
as RD1 peptides).
Regarding HIV-specific stimuli, synthetic peptides (15 AA in length,
with 11 AA of overlapping sequential peptides) corresponding to HIV-1
consensus B of HIV-GAG protein were obtained through the Centre for
AIDS Reagents, NIBSC and donated by the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH (Bethesda, MD). The
peptides were mixed to form three different pools: a) pool 1 of HIV-GAG
constituted to peptides from 1 to 41 and used at (2 μg/ml)pep; b) pool 2
of HIV-GAG constituted to peptides from 42 to 82 and used at (2 μg/
Fig. 1. Flow chart of the patients enrolled for the study. Eighty-six HIV-infected
patients naïve to ART were enrolled. Twelve of these patients were HIV-TB.
Among the 74 participants without active TB, 15 resulted HIV-LTBI. Among the
total participants prospectively enrolled, 24 were followed overtime, 8 without
TB co-infection (HIV), 9 HIV-TB and 7 HIV-LTBI. Footnotes: HIV: human im-
munodeficiency virus; TB: active tuberculosis; LTBI: latent TB infection.
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ml)pep; c) pool 3 of HIV-GAG constituted to peptides from 83 to 123 and
used at (2 μg/ml)pep. We selected the HIV-GAG pool 2 based on our
preliminary experiments. CMV lysate (strain AD169) (Experteam,
Venice, Italy) at 5 μg/ml and SEB (Sigma, St Louis, MO, USA) at 200 ng/
ml were used as an unrelated antigen and positive control, respectively.
PBMC were co-stimulated with anti-CD28 and anti-CD49d mono-
clonal antibodies (mAb) at 2 μg/ml each (BD Bioscience, San Jose,
USA). The following fluorescently conjugated mAb were used: anti-CD3
allophycocyanin (APC)-Vio770, anti-CD8 VioBlue, anti-CD4 peridinin
chlorophyll protein (PerCP)-Vio700, anti-CD45RA phycoerythrin (PE)-
Vio770, anti-CCR7 VioGreen, anti-IFN-γ APC, anti-TNF-α fluorescein
isothiocyanate (FITC) and anti-IL-2 PE (all mAb from Miltenyi Biotec).
2.3. Intracellular staining assay (ICS)
Fresh PBMC were isolated using Ficoll density gradient centrifuga-
tion, and 1× 106 cells/ml were cultured overnight with stimuli (37 °C
and 5% CO2) in 10% fetal bovine serum (PAA Laboratories GmbH,
Pasching, Austria) in RPMI-1640 (Gibco, CA, USA). BD Golgi Plug was
added after 1 h of stimulation to prevent cytokine secretion.
Intracellular staining (ICS) was performed after 16 h of incubation.
Unstimulated PBMC served as a negative control. PBMC were stained
with mAb for surface markers, fixed in 4% paraformaldehyde and
permeabilized with PBS-1% BSA −0.5% saponin-0.1% NaN3 and then
stained with mAb for intracellular cytokines. Cells were fixed again in
2% paraformaldehyde, and at least 200,000 lymphocytes were acquired
using a FACSCanto II flow cytometer (BD Biosciences).
2.4. Flow cytometry data analysis
Multiple-parameter flow cytometry data were analyzed using
FlowJo (Tree Star Inc., San Carlos, CA), Pestle and SPICE software
(provided by Dr. Roederer, Vaccine Research Center, NIAID, NIH, USA,
28). Cells were gated according to forward and side scatter plots and
the frequency of total cytokines producing CD4+ and CD8+ T-cells was
evaluated, using Boolean combination gates. Background cytokine
production in the negative control of the ICS assay was subtracted from
each stimulated condition. A positive cytokine response was defined as
at least twice the background. A frequency of any cytokine-producing
T-cells (IFN-γ and/or TNF-α and/or IL-2) of at least 0.03% was con-
sidered as a positive CD4+ and CD8+ T-cell response.
In preliminary experiments, we tested the quality of our fluorescent
antibodies using isotype control. Moreover, to properly interpret flow
cytometry data, we performed the Fluorescence Minus One (FMO)
Control. FMO control contains all the fluorochromes in a panel, except
for the one that is being measured. Using FMO it is possible to identify
any potential spread of the fluorochromes into the channel of interest.
All donors were responsive to the SEB positive control in the ICS
assay. Fig. 2 shows representative flow cytometry analyses of the CD4+
(Fig. 2A) and CD8+ (Fig. 2B) T-cell functional profile in response to
Mtb, HIV-GAG, CMV, and SEB stimulation in one HIV-LTBI patient
before starting the therapies.
The responses were evaluated in terms of number of responders to
the stimulus used and based on the frequency of total cytokine response
observed.
Phenotypical analysis of different antigen-memory response of
CD4+ and CD8+ T-cells was evaluated by flow cytometry according to
the expression of the memory/effector surface markers CD45RA and
CCR7. The memory status of antigen-specific CD4+ or CD8+ T-cells
was evaluated on differently gated CD4+ and CD8+ T-cells, respec-
tively. In particular, the phenotypical analysis was performed within
the gates defined as total CD4+ T-cell response and total CD8+ T-cell
response, identifying CD4+ and CD8+ T-cells only in the subjects with
a positive cytokine response to the antigens.
The analysis was performed before (pre-therapy) and after a median
of 1 year of ART therapy initiation (post-therapy). For patients with
active TB or LTBI “post-therapies” indicated during ART and after the
end of TB treatment or TB preventive therapy, respectively. The fre-
quency of total cytokine expression (IFN-γ, TNF-α and IL-2) and the
phenotype was evaluated by flow cytometry in CD4+ and CD8+ T-cells
Ag-specific response.
The analysis of the total enrolled participants was performed
blinded to the initial LTBI status of the patients (active TB status was
known based on the initial Mtb isolation from sputum culture).
Independent blinded analysis was then performed using the same
gating strategy by two authors (TC and after, by EP). Concordance of
the analyses was 90% and agreement was achieved by discussion.
2.5. Statistical analysis
Data were analyzed using SPSS software (Version 19 for Windows,
Italy SRL, Bologna, Italy). For continuous measures, medians and in-
terquartile range (IQR) were calculated, the Kruskal-Wallis and Mann-
Whitney tests were used to analyze unpaired data to compare the
groups, whereas Wilcoxon test was used for paired data. For non-con-
tinuous measures the Chi-square or Fischer’s test was used. P values as
≤0.05 were considered significant.
Table 1
Demographic and epidemiological characteristics of the subjects enrolled in the study pre-ART and TB therapy.
Naïve HIV-infected
HIV HIV-LTBI HIV-TB Total p value
N (%) 8 (33.3) 7 (29.2) 9 (37.5) 24 (100)
Median Age (IQR) 38.0 (29.0–43.5) 37.0 (35.0–41.0) 33.0 (26.5–44.0) 36.5 (30.2–42.7) 0.9a
Female gender (%) 4 (50.0) 1 (14.3) 0 5 (20.8) 0.04b
Origin (%) 0.2b
Italy 5 (62.5) 1 (14.3) 1 (11.1) 7 (29.2)
Western Europe 1 (12.5) – – 1 (4.2)
Eastern Europe – 2 (28.6) 3 (33.3) 5 (20.8)
Africa – 1 (14.3) 2 (22.2) 3 (12.5)
South America 2 (25.0) 3 (42.8) 3 (33.3) 8 (33.3)
BCG status (%) 0.04b
Vaccinated 3 (37.5) 6 (85.7) 8 (88.9) 17 (70.8)
Unvaccinated 5 (62.5) 1 (14.3) 1 (11.1) 7 (29.2)
HIV: human immunodeficiency virus; LTBI: latent tuberculosis infection; TB: tuberculosis; IQR: interquartile range;
BCG: Bacillus Calmette et Guérin.
a Kruskal-Wallis test.
b Chi-square test.
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3. Results
3.1. Comparison of the absolute number of CD4+ and CD8+ T-cells before
and after therapies
First, we studied the consistence of CD4+ and CD8+ T-cell popu-
lations in the three experimental groups before and after therapies. The
CD4+ T-cell absolute counts significantly differed among the analyzed
groups at baseline in fact, the median of CD4+ in HIV and HIV-LTBI
was 482 cell/mm3 and 483 cell/mm3 while in HIV-TB was 253 cell/
mm3. After therapies, the median of CD4+ T-cells absolute number
increased in all the groups (521 cell/mm3, 683 cell/mm3 and 278 cell/
mm3 for HIV, HIV-LTBI and HIV-TB, respectively) when compared to
the pre-therapy values (Table 2). When the relative proportions of
CD4+ T-cells were countered the proportions at baseline were higher in
HIV and HIV-LTBI (23.7% and 23.4%, respectively) compared to that
observed in the HIV-TB group (15.8%). After therapies, percentages of
CD4+ T-cells increased in the three groups reaching the value of 30.6%
in the HIV group.
CD8+ counts before therapies were 1116 cell/mm3, 1287 cell/mm3
and 653 cell/mm3 for HIV, HIV-LTBI and HIV-TB group respectively;
the values decreased after therapies in HIV (782 cell/mm3) and HIV-
LTBI (852 cell/mm3), while for HIV-TB we observed a weak increase
(771 cell/mm3) when compared to pre-therapy values (Table 2). The
proportion of CD8+ T-cells significantly decreased in the following
groups after therapies: HIV-LTBI, 56.3% vs 48.2%, p=0.018; HIV-TB
57.7% vs 45.2%, p=0.021 (Table 2).
As expected, the mean number of HIV-RNA (cp/μl) in the three
groups, dramatically decreased after ART: 32727 cp/μl pre-ART vs 20
cp/μl post-ART in HIV; 16689 cp/μl pre-ART vs 39 cp/μl post-ART in
HIV-LTBI, 63697 cp/μl pre-ART vs 61 cp/μl post-ART in HIV-TB
(Table 2). Based on these results, we conclude that the median of CD4+
T-cells absolute number and the median of relative proportion in-
creased after therapy in the three groups of patients, only reaching a
Fig. 2. Cytokine evaluation by flow cytometry plots. Representative flow cytometry plots of the expression of IFN-γ, TNF-α and IL-2 from CD4+ (A) and CD8+ (B) T-
cells after stimulation with Mtb (RD1 proteins or peptides), HIV-GAG, CMV and SEB, in one pre-therapies enrolled HIV-LTBI patient. “UNS” indicates unstimulated
PBMC. Cells were gated according to forward and side scatter plots and the frequency of total cytokine producing CD4+ and CD8+ T-cells was evaluated, using
Boolean combination gates. The frequency of cytokine-producing cells expressed as a percentage of the total CD4+ or CD8+ T-cell population are indicated.
Footnotes: Mtb: Mycobacterium tuberculosis; CMV: cytomegalovirus; SEB: staphylococcal enterotoxin B; IFN-γ: interferon-γ; TNF-α: tumor necrosis factor-α; IL-2:
interleukin-2.
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significant difference in the HIV-TB group as median of absolute
number. Differently, the median of CD8+ T-cells absolute count de-
creased in the group of HIV and HIV-LTBI and this was associated to a
decreased of the relative proportion in both groups. Interestingly, in the
HIV-TB we observed an increase of the median of CD8+ T-cells absolute
number accompanied by a decreased of the relative proportion; this was
due to a significant increased number of the total lymphocytes after
therapies (p=0.027) (Table 2).
3.2. Effect of ART and TB therapies on HIV/Mtb-specific CD4+ and CD8+
T-cell responses
To evaluate whether the dynamics of HIV/Mtb-specific T-cells
mirror the reconstitution of the total T-cell populations, we evaluated
the magnitude of Mtb-, HIV-GAG-, CMV- and SEB responses, before and
after starting the therapies in both CD4+ and CD8+ T-cell populations,
measuring the total response of antigen-specific T-cells in terms of total
cytokine production (IFN-γ, TNF-α and IL2) comparing HIV-LTBI and
HIV-TB groups. We have considered the capability of CD4+ and CD8+
T-cells to produce the different cytokines in relation to the memory
differentiation profiles, therefore total intracellular cytokines produ-
cing T-cells were observed following stimulation with the above cited
antigens by FACS analysis. This value is referred from now on, as the
total frequency of any cytokine-producing T-cells (IFN-γ and/or TNF-α
and/or IL-2).
3.3. CD4+ specific T-cell response
In the HIV-infected group, ART increased the proportion of re-
sponders to HIV-GAG (pre-therapy: 38% vs post-therapy: 75%). CMV
and SEB responses were detectable in all patients independently of ART
(Table 3) (Fig. 3A).
In the HIV-LTBI group, the therapies increased the proportion of
responders to RD1 proteins (pre-therapies: 43% vs post-therapies:
100%) and RD1 peptides (pre-therapies: 71% vs post-therapies: 100%)
(Table 3). Similarly, the treatments increased the proportions of re-
sponders to the recall antigens HIV-GAG (pre-therapies: 43% vs post-
therapies: 71%) and CMV (pre-therapies: 86% vs post-therapies: 100%).
Conversely, the response to SEB was detectable in all patients in-
dependently of the treatments (Table 3).
The frequency of the total CD4+ response to RD1 proteins was
significantly higher after ART and TB therapy (p=0.015) (Fig. 3A) and
a similar trend, although not significant, was observed in response to
RD1 peptides.
Differently, the frequency of CMV-specific CD4+ T-cells was lower
after the treatments compared to baseline, whereas the frequency of
HIV-GAG-specific and SEB-responding CD4+ T-cells were comparable
regardless the treatments (Fig. 3A).
In the HIV-TB group, ART and TB therapies increased the proportion
of responders to RD1 proteins and peptides (both pre-therapies: 56% vs
post-therapies: 67%), and to CMV (pre-therapies: 33% vs post-thera-
pies: 56%) (Table 3). Otherwise, the number of HIV-TB responders to
GAG significantly increased after the therapies (pre-therapies: 0% vs
post-therapies: 67%, p=0.009). Conversely, the responses to SEB were
detectable in all patients independently of the treatments (Table 3).
The frequency of the total CD4+ response to RD1 proteins and
peptides decrease after therapies, from 0.93% to 0.19% for proteins and
from 0.9% to 0.09% for peptides, as previously shown in the HIV-un-
infected patients [30]. The frequency of SEB CD4+ T-cells response was
comparable regardless the treatments (Fig. 3A). Differently, ART and
TB therapies significantly increased the frequency of the HIV-GAG-
specific T-cell response (p=0.03), whereas the frequency of CMV-
specific T-cells was decreased, although not significantly, compared to
pre-treatments (Fig. 3A).
To evaluate the impact of the CD4+ T-cell counts across the groups,
the absolute number of Ag-specific CD4+ T-cell was calculated, asTa
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described [31].
In the HIV-LTBI group we found a significant increased number of
Mtb-specific cells after ART and TB therapies (RD1 proteins p=0.015,
RD1 peptides p=0.03) (Fig. 3B).
In the HIV-TB patients the absolute number of Mtb-, CMV- and SEB-
responding CD4+ T-cells remained unchanged upon treatments,
whereas the number of HIV-GAG-specific CD4+ T-cells significantly
increased (p=0.03) (Fig. 3B).
Finally, in the HIV-infected patients, ART did not significantly
modify the absolute number of SEB-, HIV-GAG- or CMV-responding
CD4+ T-cells (Fig. 3B).
3.4. CD8+ specific T-cell response
In the HIV-infected participants, the number and frequency of re-
sponders of CD8+ T-cells to all antigens was evaluated after ART and
TB therapies (Table 4 and Fig. 4).
In the HIV-LTBI group, ART and TB therapies increased the pro-
portion of responders to RD1 peptides (pre-therapies: 14% vs post-
therapies: 43%), and decreased the number of responders to CMV (pre-
therapies: 43% vs post-therapies: 29%) (Table 4). Differently, the pro-
portion of responders to RD1 proteins, HIV-GAG and SEB remained
unchanged upon treatments (Table 4). The frequency of the total re-
sponse to both Mtb proteins and peptides decreased although not sig-
nificantly. Frequency of responses to HIV-GAG, CMV and SEB were not
significantly modified upon the treatments (Fig. 4A).
In the HIV-TB group, ART and TB therapies increased the proportion
of responders to RD1 peptides (pre-therapies: 33% vs post-therapies:
77%), HIV-GAG (pre-therapies: 22% vs post-therapies: 44%) and CMV
(pre-therapies: 11% vs post-therapies: 33%) although not significantly
(Table 4). Differently, the proportion of responders to RD1 proteins
slightly decreased after the therapies (pre-therapies: 56% vs post-
therapies: 44%). Moreover, the number of responders to SEB remained
unchanged after the therapies (Table 4). The frequency of the total
response to Mtb, HIV-GAG, CMV and SEB did not show any variation
after treatments (Fig. 4A).
Finally we did not found any variations in the absolute number of
Mtb-, HIV-GAG-, CMV-specific and SEB-CD8+ responding cells com-
paring pre- and post-therapies in all the groups analyzed (Fig. 4B).
3.5. Effect of ART on the phenotype of pathogen-specific CD4+ and CD8+
T-cells
To further investigate whether the cell maturation phenotype could
impact the replenishment capacity of HIV/Mtb-specific CD4+ and
CD8+ T-cells, we compared the differentiation profiles of Mtb-, HIV-
GAG-, CMV-, and SEB-responding CD4+ and CD8+ T-cells in terms of
total cytokine production at baseline (pre-therapies) and post-therapies.
Cumulative analyses show that after therapies the majority of the CD4+
T-cell response to Mtb and to the other unrelated antigens was
characterized by an increase of the CM and by a decrease of EM sub-
populations in all the groups analyzed (Fig. 5A–B). Conversely, the
phenotype distribution of CD8+ T-cells showed different patterns. In
HIV-LTBI subjects, after therapies an increase of N subsets and a de-
crease of EM was found in response to RD1 proteins, peptides and to
HIV-GAG (Fig. 5A–B). In HIV-TB patients, the EM phenotype was the
major subset of CD8+ T-cells in response to all stimuli and did not
change overtime, while the E subset was slightly increased after ART
and TB therapies in response to RD1 antigens (Fig. 5A–B).
4. Discussion
Although ART causes a progressive reconstitution of the number of
CD4+ T-cells in most subjects, the different degree of the recovery of
copathogen-specific CD4+ and CD8+ T-cells is poorly defined. In this
prospective study, conducted in HIV-infected participants with or
without TB co-infection, we evaluated how ART and TB therapies
concomitantly contributed to the modulation of the absolute count of
CD4+ and CD8+ T-cell, the capacity of these cells to produce several
cytokines in response to appropriate antigen stimulation and their dif-
ferent phenotype distribution.
The median of absolute number and the proportion of CD4+ T-cells
increased in all groups after therapies, although only in HIV-TB group
this increase was significant. Conversely, the median of absolute count
and proportion of CD8+ T-cells decreased in the HIV and HIV-LTBI
subjects. Interestingly, in the HIV-TB we observed a little increase of the
median of absolute number of CD8+ T-cells accompanied by a de-
creased of the relative proportion due to a significant increased number
of the total lymphocyte after therapies.
Regarding the Mtb-specific responses, ART and TB therapies in-
creased the frequency of CD4+ T-cell response to RD1 proteins in HIV-
LTBI subjects. This is in line with other reports showing an increased
IFN-γ production in response to Mtb-specific antigens after ART
[32,33]. Moreover, this data are in agreement with a recent paper [34]
showing a decreased frequency of the total cytokine response to PPD in
HIV-LTBI compared to the LTBI subjects (without HIV infection). It is
known, in fact, that HIV infection causes a depletion of the RD1-specific
T-cell clones [34] that ART may, at least partially, recover. In the
present study we show that the frequency of RD1-specific CD4+ T-cells
found in the cured TB patients (HIV-TB post therapies: median 0.09) is
similar to that one found in the HIV-LTBI after therapies (HIV-LTBI:
median 0.075) suggesting that this level could be associated to myco-
bacterial containment.
Interestingly, in the HIV-TB group the therapies significantly in-
creased the CD4+ T-cells counts compared to baseline while the fre-
quency of CD4+ T-cells response to TB-Ags decreased. These results are
in agreement with those reported by Day C. et al. [30] showing that in
TB patients (without HIV infection), the CD4-specific T-cells response
decrease after TB therapy and correlating it with the decrease of the
mycobacterial load. In the present manuscript, in those with active TB
Table 3
Impact of ART and TB therapies on the CD4+ T-cell response to specific stimuli in HIV-infected subjects, HIV-LTBI and HIV-TB patients.
HIV HIV-LTBI HIV-TB
Pre-ART Post-ART p value Pre-therapies Post-therapies p value Pre-therapies Post-therapies p value
RD1 proteins Number of Responder over total (%) – – – 3/7 (43) 7/7 (100) 0.07 5/9 (56) 6/9 (67) 1
RD1 peptides Number of Responder over total (%) – – – 5/7 (71) 7/7 (100) 0.46 5/9 (56) 6/9 (67) 1
HIV-GAG Number of Responder over total (%) 3/8 (38) 6/8 (75) 0.31 3/7 (43) 5/7 (71) 0.59 0/9 (0) 6/9 (67) 0.009
CMV Number of Responder over total (%) 6/8 (75) 6/8 (75) 1 6/7 (86) 7/7 (100) 1 3/9 (33) 5/9 (56) 0.64
SEB Number of Responder over total (%) 8/8 (100) 8/8 (100) 1 7/7 (100) 7/7 (100) 1 9/9 (100) 9/9 (100) 1
HIV: human immunodeficiency virus; LTBI: latent tuberculosis infection; TB: tuberculosis; ART: antiretroviral therapy; RD: region of difference; CMV: cytomega-
lovirus; SEB: staphylococcal enterotoxin B.
Fisher's exact test was used for the comparisons of the number of responders between pre- and post-therapies.
The bold values are the p values ≤0.05 to be considered as significant.
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Fig. 3. Effect of ART and TB therapies on RD1 proteins- and RD1 peptides- (Mtb-specific antigens), HIV-GAG-, CMV-, and SEB-specific CD4+ T-cell responses in the
different groups of patients analyzed. Frequency (A) and absolute number (B) of RD1 proteins-, RD1 peptides-, HIV-GAG-, CMV- and SEB-specific CD4+ T-cell
response before and after ART and TB therapies. Statistical comparisons were performed using a Wilcoxon matched-pairs test and Mann-Whitney un-pairs test.
Footnotes: HIV: human immunodeficiency virus; TB: active tuberculosis; LTBI: latent TB infection; RD: region of difference; CMV: cytomegalovirus; SEB: staphy-
lococcal enterotoxin B.
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that are also HIV-coinfected, there is a dissociation between an in-
creased total CD4+ T-cells count, due to the HIV-load reduction by
ART, and a decreased CD4-specific response that associate with a re-
duction of Mtb load due to TB therapy. It is important to mention that
the overall functional restoration of CD4+ and CD8+ T-cells is a slowly
process, that is evident after more than 2 years of complete viral sup-
pression [35]. Therefore, for a more accurate immune assessment we
are planning a subsequent evaluation after a longer observation time.
In this study we show that the number of CD8+ T-cells responders to
RD1 peptides increased after therapies in HIV-LTBI and HIV-TB groups,
although no significant variation of the CD8-specific response fre-
quency was found. Conversely, using different stimuli, it has been
shown a decline of the Mtb peptide-specific CD8+ T-cells after anti-TB
therapy in patients with active TB either HIV-TB co-infected [36] or
without HIV infection [37]. Therefore, it would be important to study
these responses after longer-term ART and using immune panels in-
volving several stimuli. This approach would lead to a more definitive
conclusion on the restoration of pathogen-specific immunity.
Finally, comparing active TB versus LTBI, we found that the Mtb-
specific CD8+ T-cell frequency (in response to peptides) is higher in the
active TB (HIV-TB) compared to those with LTBI (HIV-LTBI) at baseline.
This is similar to the findings reported in studies conducted in HIV-
uninfected subjects [30,38]. Interestingly, it has also been shown that
HIV reduces the Mtb-specific CD8+ T-cell response to ESAT-6/CFP10
proteins in those latently infected [39].
We also assessed the phenotypic and functional characterizations of
Mtb-specific CD4+ and CD8+ T-cells to evaluate whether distinct T-cell
functional signatures are correlated with a particular skewed effector
phenotypes. We found that the therapies increased the Mtb-specific
CD4+ CM T-cell response. These data are in line with a previous study
demonstrating that TB treatment reduces the frequency of EM PPD-
specific CD4+ T-cells while simultaneously increasing the proportion of
specific T-cells with CM phenotype [40]. Moreover, it has been de-
monstrated that the restoration of Mtb-specific CD4+ T-cells depends
on the memory status as proportion of the central memory and transi-
tional memory cells present prior to therapy [31]. Similarly, Wilkinson
et al. found that ART expanded the CM cell subset [41].
Together these data confirm that CD4+ T-cells are required for an
optimal protective immune response against Mtb, especially in the HIV-
LTBI subjects that are those at higher risk to progress to disease. This is
due to the fact that Mtb-specific CD4+ T-cell are preferentially infected
and depleted during early HIV infection [23,42]. ART preferentially
reconstitutes the CD4+ T-cells responding to frequently encountered
antigens, such as CMV or Mtb but not to tetanus [43–45] indicating the
presence of different programs of cell reconstitution.
The analysis of the phenotype distribution of CD8+ T-cell in re-
sponse to Mtb, HIV-GAG and to CMV antigens highlighted a different
phenotype distribution before and after ART and TB therapies. In fact,
we found in HIV-LTBI subjects, an increase of CD8+ T-cells with a N
phenotype and a decrease of EM in response to RD1 antigens, while in
HIV-TB patients, the EM phenotype was the major subset of CD8+ T-
cells in response to all stimuli, while the E subset was slightly increased
after ART and TB therapies in response to RD1 antigens. Cells with N
phenotype may resemble the recently described memory stem cell
subset characterized by a greater ability to proliferate and persist long,
if compared with CM cells [46,47]. Then, the memory status before the
ART could affect the recovery of Ag-specific CD8+ T-cells. Therefore,
the response of antigen specific CD8+ T-cells could be related to the
stage of Mtb infection/disease, reflecting the ability of the different
phenotypes in controlling the pathogen.
The analysis of the cell phenotype distribution in response to viruses
correlate with the type of disease induced, acute (Influenza, Yellow
Fever, Poliovirus, Hepatitis A, etc) versus chronic disease (CMV, Epstein
Barr Virus (EBV), HIV-1, JC Virus (JCV) etc). In this model it was found
an association of E phenotype with a controlled chronic infection
whereas the EM phenotype was associated with an uncontrolled chronic
infection [48]. Our results suggest that this may be also the case for
Mtb-specific CD8+ T-cells in HIV-TB patients. From this analysis, it is
evident that the type of antigen and the different stage of infection are
involved in the phenotype distribution of CD8+ T-cells, but further
studies are needed to better attribute any functional role.
A potential limitation of the present study is the relatively small
number of participants included. This is the consequence of the fact that
the study was conducted in a low TB endemic country in which also HIV
prevalence is low, and this implies a fewer number of HIV co-infected
subjects. Furthermore, we carried out our study only on the short-term
restoration of pathogen-specific immunity (after 1 year of ART and TB
therapies). Although the patients recovered the immunological para-
meters in terms of reduction of HIV replication and improved CD4+ T-
cell counts, the study would benefit of monitoring responses after
longer-term therapy to provide more definitive conclusions on the re-
storation of pathogen-specific immunity. On the other hand, the present
study was very systematic in terms of groups analyzed (HIV, HIV-LTBI
and HIV-TB), experimental tools used (Mtb-specific and unrelated recall
antigens employed), integrity and reproducibility of the results ob-
tained, evaluation of the total cytokine responses and memory status in
both CD4+ and CD8+ T-cell subsets, which make our findings robust.
In summary, we show here that the dynamics of Mtb- and HIV-GAG-
and CMV-specific CD4+ and CD8+ T-cell recovery in HIV co-infected or
not co-infected participants are distinct, demonstrating that non all T-
cell subsets have the same recovery capacity. Partial reestablishment of
functional immunity could affect the choice of the treatment in HIV-
infected population. Overall, our findings underscore the complexity of
immune reconstitution on ART and TB therapy and the importance of
preserving functional immunity with these treatments in HIV-infected
participants.
Funding
The study was supported by grants from the Italian Ministry of
Health: RF-2011-02349395, 97/RF-2011-02348713, 54/GR-2011-
02350886 and “Ricerca Corrente” and grants from the European Union:
Table 4
Impact of ART and TB therapies on the CD8+ T-cell response to specific stimuli in HIV-infected subjects, HIV-LTBI and HIV-TB patients.
HIV HIV-LTBI HIV-TB
Pre-ART Post-ART p value Pre-therapies Post-therapies p value Pre-therapies Post-therapies p value
RD1 proteins Number of Responder over total (%) – – – 2/7 (29) 2/7 (29) 1 5/9 (56) 4/9 (44) 1
RD1 peptides Number of Responder over total (%) – – – 1/7 (14) 3/7 (43) 0.56 3/9 (33) 7/9 (77) 0.15
HIV-GAG Number of Responder over total (%) 5/8 (63) 5/8 (63) 1 3/7 (43) 3/7 (43) 1 2/9 (22) 4/9 (44) 0.62
CMV Number of Responder over total (%) 1/8 (13) 1/8 (13) 1 3/7 (43) 2/7 (29) 1 1/9 (11) 3/9 (33) 0.58
SEB Number of Responder over total (%) 8/8 (100) 8/8 (100) 1 7/7 (100) 7/7 (100) 1 9/9 (100) 9/9 (100) 1
HIV: human immunodeficiency virus; LTBI: latent tuberculosis infection; TB: tuberculosis; ART: antiretroviral therapy; RD: region of difference; CMV: cytomega-
lovirus; SEB: staphylococcal enterotoxin B.
Fisher's exact test was used for the comparisons of the number of responders between pre- and post-therapies.
T. Chiacchio et al. Immunology Letters 198 (2018) 33–43
40
Fig. 4. Effect of ART and TB therapies on RD1 proteins- and RD1 peptides- (Mtb-specific antigens), HIV-GAG-, CMV-, and SEB-specific CD8+ T-cell responses in the
different groups of patients analyzed. Frequency (A) and absolute number (B) of RD1 proteins-, RD1 peptides-, HIV-GAG-, CMV- and SEB-specific CD8+ T-cell
response before and after ART and TB therapies. Statistical comparisons were performed using a Wilcoxon matched-pairs test and Mann-Whitney un-pairs test.
Footnotes: HIV: human immunodeficiency virus; TB: active tuberculosis; LTBI: latent TB infection; RD: region of difference; CMV: cytomegalovirus; SEB: staphy-
lococcal enterotoxin B.
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